TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clinical trial NCT02322281 · TERMINATED
Trial details
- NCT number
- NCT02322281
- Sponsor
- Clovis Oncology, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-01
- Primary completion
- 2018-03-29
- Enrollment
- 149
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.